文献速递泌尿男性生殖肿瘤

前列腺切除术后放疗作为辅助或挽救治疗的系统综述

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.
PubMed 文献 · JAMA Oncol · 2020-01-01

该系统综述检索2014至2019年文献,最终纳入27篇,评估前列腺切除术后放疗的时机、范围及联合雄激素剥夺治疗(ADT)与淋巴照射的证据。结论提示,对不良病理特征患者应考虑术后放疗, favorable特征者可密切监测PSA;高风险队列应考虑ADT和盆腔淋巴照射;PET成像与分子检测作为决策工具尚未证实。

要点

  • 不良病理特征(如包膜外侵犯或切缘阳性)患者应考虑术后放疗以改善疾病控制。
  • 低Gleason评分但切缘阳性的有利风险人群,密切监测PSA可作为部分患者的选择。
  • 高PSA、高Gleason评分、精囊侵犯或淋巴结阳性者,术后放疗应联合ADT并考虑盆腔淋巴照射。

核心结论

  • 前列腺切除术后放疗应考虑用于具有不良病理特征的前列腺癌患者。
  • 经仔细选择的有利特征患者,密切监测PSA是一种选择。
  • 较高风险队列(如较高PSA值、较高Gleason评分)应考虑ADT和盆腔淋巴照射。
  • PET成像和分子研究作为决策工具仍未获证实。

研究设计与样本

  • 系统综述检索MEDLINE(Ovid)、Embase(Elsevier)和Cochrane Library(Wiley)数据库及临床试验注册库。
  • 筛选548条引用后,最终纳入27篇文章。

主要发现

  • 除常规成像外,基于正电子发射断层扫描(PET)的放射性示踪剂可协助疾病定位。
  • PET成像可能影响放疗管理,但相关研究正在进行,且需考虑低PSA水平检出率有限和区域敏感性等局限性。
  • 可用基因组分类器可对患者进行风险分层或评估放疗的潜在额外获益,前瞻性验证正在合作组试验中进行。
  • 基于不良病理特征(如包膜外侵犯或切缘阳性)的辅助放疗有利于疾病控制,但是否转化为更有意义的临床获益(如改善总生存和减少转移)尚不清楚,仅1项较老的前瞻性随机研究证实。
  • 初步数据提示,对于相对有利风险人群(低Gleason评分但切缘阳性),监测PSA可能是部分男性的合理替代方案。

临床怎么用

  • 对具有不良病理特征的前列腺癌患者,术后应考虑放疗。
  • 对经仔细选择的有利特征患者,可选择密切监测PSA。
  • 对较高风险队列(如较高PSA值、较高Gleason评分),应考虑ADT和盆腔淋巴照射。
  • PET成像和分子研究作为决策工具尚未证实,不应常规用于治疗决策。

局限性

  • PET成像在低PSA水平检出率有限且区域敏感性有限。
  • 基因组分类器作为决策工具尚需前瞻性验证。
  • 辅助放疗转化为总生存和减少转移的临床获益仅由1项较老的前瞻性随机研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: After radical prostatectomy, adverse pathologic features and postoperative prostate-specific antigen (PSA) levels can herald disease recurrence or progression. Postoperative radiotherapy (RT) remains beneficial in this setting. OBJECTIVE: To examine the evidence supporting the use of postoperative RT as well as recent advances that help determine timing, scope, and use in combination with androgen deprivation therapy (ADT) with or without lymphatic irradiation. EVIDENCE REVIEW: A search was conducted of MEDLINE (Ovid), Embase (Elsevier), and the Cochrane Library (Wiley) databases, in addition to clinical trial registries. The reference list of included studies was reviewed for relevant articles. The search was limited to studies published between January 1, 2014, and December 31, 2019. FINDINGS: After 548 citations were screened, 27 articles were selected for inclusion. In addition to conventional imaging, positron-emission tomographic (PET)-based radiotracers can aid in disease localization. While PET imaging may influence management with RT, studies are underway examining this issue, and several limitations must be considered, such as limited detectability at lower PSA levels and regional sensitivity. Available genomic classifiers can risk stratify patients or assess potential added benefit of RT. Prospective validation is underway with cooperative group trials. Adjuvant RT, on the basis of adverse pathologic features (such as extraprostatic extension or positive margins) is beneficial in terms of disease control, but it is unclear whether this therapy translates into more meaningful clinical benefit (eg, improved overall survival and a reduction in metastasis), which has been demonstrated by only 1 older, prospective randomized study. Preliminary data suggest that for a relatively favorable-risk population (low Gleason score but with positive margins), PSA monitoring may be a reasonable alternative in some men. Use of androgen deprivation therapy and lymphatic irradiation should be considered in higher-risk cohorts (those with high PSA, high Gleason score, seminal vesicle invasion or node positivity) in conjunction with postoperative RT. CONCLUSIONS AND RELEVANCE: The findings of this review suggest that postprostatectomy RT should be considered for men with prostate cancer in the setting of adverse pathologic features; in carefully selected patients with favorable characteristics, close PSA monitoring is an option. Androgen deprivation therapy and pelvic lymphatic irradiation should be considered for higher risk cohorts (eg, higher PSA values, higher Gleason score). PET imaging and molecular studies remain unproven as decision tools.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sachdev S, Carroll P, Sandler H, et al. Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. JAMA Oncol. 2020. PMID: 32852528. doi:10.1001/jamaoncol.2020.2832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。